Darshna Goordeen

Darshna Goordeen

Auto-generated profile, based on publicly available information

Darshna Goordeen

Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2025 in Journal of the American Geriatrics Society
Verified
Journal Article
Open access
AMAisling M. McEvoy
Aisling M. McEvoy
ALAili V. Langford
Aili V. Langford
SLShin J. Liau
Shin J. Liau
DGDarshna Goordeen
Darshna Goordeen
EREmily Reeve
Emily Reeve
JTJustin Turner
Justin Turner
Background: Benzodiazepine receptor agonists (BZRAs) (benzodiazepines and z‐drugs) may provide limited benefits in the management of insomnia when used short‐term. However, they increase the risk of harms including falls, fractures, hospitalizations, and cognitive impairment. Deprescribing (cessation) of BZRAs may be beneficial for older adults and people living with cognitive impairment as they are at heightened risk of adverse events. This review investigated the effects of patient‐directed, non‐pharmacological interventions to support deprescribing of BZRAs used for insomnia in older adults and people living with cognitive impairment.Methods: Embase, CENTRAL, Scopus, and Medline were searched in January 2024 with no publication date restrictions. Screening, data extraction, and risk of bias assessments (ROB2 for randomized studies, ROBINS‐I for non‐randomized studies) were conducted independently by two authors. Outcomes of interest included the proportion of participants who ceased BZRAs, reduction in BZRAs, switching to another medication, sleep outcomes, and clinical outcomes. Studies were included if they investigated BZRA deprescribing in older adults (≥ 65 years) or people living with cognitive impairment.Results: Seventeen reports analyzing 16 studies in hospital, community, and aged care settings were included. BZRA cessation rates ranged between 23% to 72% for written education (n = 6); 14% to 57% for combined written and verbal education (n = 5); and 9% to 100% for multi‐component interventions (n = 6). One report investigated a BZRA deprescribing educational intervention in people with cognitive impairment and found comparable effectiveness to participants without cognitive impairment. Most studies were at a high risk of bias.Conclusions: Patient‐directed interventions led to BZRA cessation, although there was significant variability between studies. It is unknown if all interventions examined are similarly effective for people living with cognitive impairment. Further research investigating approaches to deprescribing BZRAs in older adults or people with cognitive impairment is required.

17 April 2025 in Geriatrics & Gerontology International
Verified
Journal Article
Open access
DGDarshna Goordeen
Darshna Goordeen
JBJ Simon Bell
J Simon Bell
YEYoumna Elsedfy
Youmna Elsedfy
SFSoroush Fariman
Soroush Fariman
SHShota Hamada
Shota Hamada
EREmily Reeve
Emily Reeve
Aim: The Western Pacific region has the fastest aging population and 38% of the world's diabetes population. It is unknown to what extent medication management recommendations are included for older adults in type 2 diabetes (T2D) clinical practice guidelines (CPGs).Method: MEDLINE, Embase, Scopus, guideline‐specific registries and gray literature searches were performed in November 2024. Data were extracted on guideline characteristics and recommendations relevant to older adults, dementia, frailty, co‐morbidities associated with aging or end‐of‐life. Quality appraisal was performed using the AGREE II (Appraisal of Guidelines, Research and Evaluation) tool.Results: From the 37 countries and areas of the Western Pacific region, 16 CPGs were identified, of which 15 included 1–29 relevant recommendations. Thirteen CPGs recommended less stringent and/or individualized glycemic targets focused on reducing hypoglycemia for older adults. Five CPGs recommended individualized antihyperglycemic treatment choices. Seven CPGs included recommendations about de‐intensification/simplification of complex regimens. The quality of CPGs varied, with scope and purpose rated the highest.Conclusions: There was heterogeneity in the number of recommendations within CPGs; however, none comprehensively addressed the T2D medication management needs of older adults or those living with dementia, frailty or receiving end‐of‐life care. Collaboration between diabetes and geriatric societies as well as the assistance of higher‐income countries in helping those with less resource availability could provide a way forward to improving future CPGs. Geriatr Gerontol Int 2025; 25: 717–729.

16 June 2026 in The Lancet Healthy Longevity
Verified
Journal Article
Open access
OHOlivia K Hopkinson
Olivia K Hopkinson
JCJan Chobanov
Jan Chobanov
DGDarshna Goordeen
Darshna Goordeen
KMKenneth K C Man
Kenneth K C Man
IWIan C K Wong
Ian C K Wong
WLWallis CY Lau
Wallis CY Lau
Antipsychotic use in people living with dementia has been linked to serious adverse outcomes. Guidelines recommend limiting antipsychotic treatment to short-term use (<12 weeks), followed by tapering and cessation. However, antipsychotic treatment in routine practice often exceeds the recommended duration. The effect of discontinuing antipsychotics on reducing adverse outcomes in practice remains unclear. We aimed to use linked primary and secondary care data in England to investigate whether tapering or abrupt discontinuation of antipsychotics, versus continuation, affected the risk of stroke, death, fracture, delirium, and pneumonia in people living with dementia. Using UK primary care data from the Clinical Practice Research Datalink, linked with hospital and mortality data from Jan 1, 1998, to March 31, 2021, we emulated two sets of target trials, one after 12 weeks of antipsychotic treatment and another after 24 weeks of antipsychotic treatment, to compare continuing treatment versus tapering treatment and continuing treatment versus abrupt discontinuation of treatment. Patients aged 65 years and older at incident dementia diagnosis with antipsychotic treatment duration of at least 12 weeks were included. Study outcomes were incidence of fracture, stroke, hospitalisation for delirium, hospitalisation for pneumonia, and all-cause mortality within 24 months. A negative control outcome of skin conditions was included to measure potential unmeasured confounding. A clone-censor-weight approach was used with a 6-month grace period allowed for discontinuing antipsychotics. Weighted pooled logistic regression models were used to estimate 24-month absolute risk differences (ARDs). 134 549 eligible patients had a new antipsychotic treatment after dementia diagnosis, of whom 24 822 (18·4%) had a treatment period of at least 12 weeks and 16 795 (12·5%) had a treatment period of at least 24 weeks and met the eligibility criteria. The mean age was 83·57 (SD 7·07) in the 12-week trial and 83·65 (SD 7·02) in the 24-week trial; 16 725 (67·4%) of 24 822 patients were female and 8097 were male in the 12-week trial and 11 523 (68·6%) of 16 795 patients were female and 5272 were male in the 24-week trial. Compared with continuation after 12 weeks of treatment, estimated risks of delirium and fracture under the tapering strategy corresponded to 24-month ARDs of -2·46% (95% CI -4·10 to -1·27) and -2·80% (-4·14 to -1·29), respectively. Estimated risks for stroke, pneumonia, and all-cause mortality were similar between strategies. No difference in risk was observed for the negative control outcome. Similar results were found after 24 weeks of treatment and in sensitivity analyses. Irrespective of method, antipsychotic discontinuation decreased the risk of delirium and fracture. Antipsychotics can be discontinued safely when treatment duration has exceeded guideline recommendations without increasing the risk of death, stroke, or pneumonia in those living with dementia. PharmAlliance Research Clusters for Doctoral Training.

19 April 2025
Verified
Book Chapter
Closed access
PDF file
ALAili V. Langford
Aili V. Langford
FMFrank Moriarty
Frank Moriarty
DGDarshna Goordeen
Darshna Goordeen
BFBarbara Farrell
Barbara Farrell
EREmily Reeve
Emily Reeve

30 July 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MAMaria J. Alfonso Arvez
Maria J. Alfonso Arvez
SWSam Wade
Sam Wade
DGDarshna Goordeen
Darshna Goordeen
JIJenni Ilomaki
Jenni Ilomaki
ACAmanda J. Cross
Amanda J. Cross
GTGeorge S. Q. Tan
George S. Q. Tan
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are increasingly prescribed for type 2 diabetes and weight management. However, conflicting evidence from preclinical, clinical, and pharmacovigilance studies suggests potential neuropsychiatric effects. This study examined associations between GLP‐1RA use and initiation of a range of neuropsychiatric medications using real‐world prescription data. A Prescription Sequence Symmetry Analysis was conducted using Australia's Pharmaceutical Benefits Scheme 10% random sample between July 1, 2013 and December 31, 2024. Individuals with an incident dispensing of both a GLP‐1RA and a neuropsychiatric medication were included. Outcomes comprised antidepressants, medication for substance use disorder (SUD), antipsychotics, psychostimulants, antidementia medications, antiparkinsonian medications, antiepileptics, and antimigraine agents. Adjusted sequence ratios (aSRs) with 95% confidence intervals (CIs) were calculated using a one‐year exposure window, with sensitivity analyses varying various time windows. Among 2,033 individuals, semaglutide was the most common GLP‐1RA (50.6%), followed by exenatide (27.5%) and dulaglutide (21.9%). GLP‐1RA initiation was inversely associated with initiation of antidepressants (aSR: 0.85; 95% CI: 0.76–0.94) and medications for SUD (aSR: 0.70; 95% CI: 0.51–0.88). No significant associations were observed for other neuropsychiatric outcomes. GLP‐1RA use was inversely associated with subsequent initiation of antidepressants and medications for SUD, while no associations were identified for other neuropsychiatric marker medications. These findings highlight the need for further studies to clarify the nature and magnitude of these potential neuropsychiatric associations with GLP‐1RAs.

27 September 2026 in European Geriatric Medicine
Verified
Journal Article
Open access
PDF file
DGDarshna Goordeen
Darshna Goordeen
OHOlivia K. Hopkinson
Olivia K. Hopkinson
EREmily Reeve
Emily Reeve
JNJoshua D. Niznik
Joshua D. Niznik
WLWallis C. Y. Lau
Wallis C. Y. Lau
JBJ. Simon Bell
J. Simon Bell
Purpose: To investigate the prevalence of type 2 diabetes (T2D) medication use in the final 3,6, 9, and 12 months of life and explore patient factors associated with discontinuation in the 6 months prior to death in people living with dementia in the UK and Australia. Methods: Linked hospital and administrative data were used from the UK and Australia. We included individuals who died between July 2013 and June 2018. Logistic regressions estimated the association between age, sex, cardiovascular disease, chronic kidney disease (CKD), and cancer with discontinuation of T2D medications. Results: 10,088 UK and 6,436 Australian individuals were identified. From those supplied insulin in the last 12 months of life, there was a 25.6% reduction in use in the UK and 43.5% in Australia in the last 3 months of life, but minimal reduction in other medication classes. CKD was associated with metformin discontinuation in the last 6 months of life in the UK (OR 1.05, 95% CI 1.03–1.07) and Australia (OR 1.60, 95% CI 1.15–2.12). Conclusion: Guideline-concordant discontinuation of metformin in the last 6 months of life was observed in those with CKD. Decreased insulin supply in those living with dementia was observed. There were lower rates of discontinuation of other glucose-lowering medications in the UK and Australia.